DGX

Rating neutralTentativeAI MemoPost-earnings T+1

Quest Diagnostics

As of 2026-10-23/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-23 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Cyber-incident scope and remediation • 2026-12-31

Base target: $250 / p=50% prob

Biggest risk

Revenue per requisition declined 4.2%, making mix and reimbursement important offsets to volume growth. The cyber incident adds an unquantified liability and reputation risk while its scope remains unresolved. [#SEC-8K-2026-10-22] [#8-K-2026-10-22]

Invalidation

Break below $205 or thesis failure.

What would change my mind?

Q3 adjusted EPS exceeded the cited $2.85 pre-release consensus by $0.15, and Quest lifted full-year guidance after 14.4% organic requisition-volume growth. Continued growth across physician, hospital and consumer channels could support estimates. [#SEC-8K-2026-10-22] Zacks consensus

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-23

Base target

$250

p=50%

Bull target

$275

p=30%

Bear target

$205

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q3 beat and raised 2026 guidance
Advanced diagnostics and laboratory technology rollout
Q3 adjusted EPS exceeded the cited $2.85 pre-release consensus by $0.15, and Quest lifted full-year guidance after 14.4% organic requisition-volume growth.

BearKey bullets

Project Nova's first-lab deployment is not expected until fall 2027, leaving rollout timing and returns subject to execution risk.
[#SEC-8K-2026-10-22]
Q3 revenue per requisition fell 4.2%; a slower volume trend or adverse mix could erode the benefit of the raised guidance.

WatchKey bullets

Cyber-incident scope and remediation

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $250 (p=50%)

Target spread vs base: +10% / -18%

Scenario probabilities

Bull Target: $275 (p=30%)Base Target: $250 (p=50%)Bear Target: $205 (p=20%)

Commentary

The October 22 close of $243.28 was about 1.8% above the prior close, despite a sharp intraday low; the mixed trading should not be attributed solely to earnings because the cyber disclosure arrived the same day. Historical prices The beat and guide raise support a more positive thesis than the April baseline, consistent with the packet's positive deterministic prior. Verified post-print analyst target or estimate revisions are unavailable at this T+1 stage, and the unresolved cyber incident warrants monitoring rather than a stronger rating.

As of 2026-10-23 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q3 beat and raised 2026 guidance
Advanced diagnostics and laboratory technology rollout

Scenarios

Bull Target (Scenario probability)

$275 / p=30% prob

Base Target (Scenario probability)

$250 / p=50% prob

Bear Target (Scenario probability)

$205 / p=20% prob

Analysis 2026-10-23 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.15

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Cyber-incident scope and remediation
Quest disclosed unauthorized access to its Quanum LSM system and believes certain patient records were accessed. It said operations had not been materially disrupted, but the scope remains under investigation. Findings on exposure, remediation costs or legal consequences could materially change the risk assessment. [#8-K-2026-10-22]
Prob 55.00% • Move -5.00% • Priced-in 35.00%
EVENT2027-03-25
Dated 2027 Investor Day
Quest scheduled an Investor Day for March 25, 2027. More detail on growth initiatives and longer-term economics could clarify whether the Q3 volume gains support durable earnings growth; no specific targets have yet been established by the cited release. [#SEC-8K-2026-10-22]
Prob 65.00% • Move 4.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

Q3 beat and raised 2026 guidance
2026-12-31
Quest reported Q3 revenue of $3.097 billion and adjusted EPS of $3.00, versus a pre-release Zacks consensus of $3.04 billion and $2.85. It raised 2026 revenue guidance to $12.065–$12.105 billion and adjusted EPS guidance to $11.25–$11.35. Organic requisition volume rose 14.4%, while revenue per requisition fell 4.2%; sustaining that volume-led growth is the key test. [#SEC-8K-2026-10-22] Zacks consensus
Prob 70% • Move 5% • Priced-in 70%

Long-term Catalysts

Months to a year

Advanced diagnostics and laboratory technology rollout
2027-10-01
Quest highlighted an expanded AD-Detect Alzheimer's testing menu and said it expects its first Project Nova lab deployment in fall 2027. Adoption and execution offer longer-duration upside, but the release does not quantify their prospective earnings contribution. [#SEC-8K-2026-10-22]
Prob 55% • Move 6% • Priced-in 35%

Risks

Project Nova's first-lab deployment is not expected until fall 2027, leaving rollout timing and returns subject to execution risk. [#SEC-8K-2026-10-22]
Q3 revenue per requisition fell 4.2%; a slower volume trend or adverse mix could erode the benefit of the raised guidance. [#SEC-8K-2026-10-22]
Quanum LSM incident scope, patient-record exposure, remediation costs and potential legal or regulatory consequences remain unresolved despite Quest reporting no material operational disruption. [#8-K-2026-10-22]

Peers

Symbol	Summary
ABT	Abbott has diagnostics exposure but is a diversified healthcare company, so it is an imperfect comparator. The available direct-peer set is narrow.
LH	Labcorp is the closest direct U.S. clinical-laboratory peer for comparing testing volumes, reimbursement pressure and operating margins; the packet provides no current peer results for a quantified relative call.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-23

Loading AI feed…

Symbol

Summary

ABT

Abbott has diagnostics exposure but is a diversified healthcare company, so it is an imperfect comparator. The available direct-peer set is narrow.

Labcorp is the closest direct U.S. clinical-laboratory peer for comparing testing volumes, reimbursement pressure and operating margins; the packet provides no current peer results for a quantified relative call.